No Data
Tiansheng Pharmaceutical Group (002872.SZ): Plans to increase capital investment in Changsheng Pharmaceutical by 29.4 million yuan.
Gelonghui, on December 27, announced that Tiansheng Pharmaceutical Group (002872.SZ) disclosed that to meet the daily Operation development needs of Changsheng Pharmaceutical, the company and Chongqing Pharmaceutical intend to increase their capital in Changsheng Pharmaceutical in proportion to their shareholding. The company plans to increase its capital in Changsheng Pharmaceutical by 29.4 million yuan from its own funds, while Chongqing Pharmaceutical intends to increase its capital in Changsheng Pharmaceutical by 30.6 million yuan in cash. The total capital increase amounts to 60 million yuan, which will be included in the registered capital of Changsheng Pharmaceutical. After the completion of this capital increase, the registered capital of Changsheng Pharmaceutical will increase from 100.6 million yuan to 160.6 million yuan, and the company will still Hold 49% of the equity in Changsheng Pharmaceutical.
Tiansheng Pharmaceutical Group (002872.SZ): The subsidiary participates in the tenth batch of national Pharmaceutical centralized procurement and plans to be selected.
On December 13, Gelonghui reported that Tiansheng Pharmaceutical Group (002872.SZ) announced that its wholly-owned subsidiary Hubei Tiansheng Pharmaceutical Co., Ltd. participated in the bidding organized by the National Organization for Pharmaceutical Joint Procurement Office for the tenth batch of nationwide centralized pharmaceutical procurement. According to the "Proposed Selection Results Announcement for National Centralized Pharmaceutical Procurement" published by the Joint Procurement Office on December 12, 2024, Hubei Tiansheng's product, aminophylline injection, is proposed to win the bid for this centralized procurement.
ST Tiansheng: Report for the third quarter of 2024
Tiansheng Pharmaceutical's Isoniazid Tablets Pass Chinese Drug Regulator's Consistency Evaluation
Tiansheng Pharmaceuticals Group (002872.SZ): Isoniazid tablets pass generic drug consistency evaluation.
Gelonghui, October 14th | tiansheng pharmaceutical group (002872.SZ) announced that the company recently received the "Drug Supplementary Application Approval Notice" issued by the National Medical Products Administration. The "Isoniazid Tablets" of the company passed the evaluation of generic drug quality and efficacy consistency. Isoniazid inhibits the synthesis of the key component mycolic acid of bacterial cell walls. At therapeutic concentrations, isoniazid has a bactericidal effect on intracellular and extracellular mycobacterium tuberculosis in the growth and reproduction period. Isoniazid tablets are suitable for: (1) various types of tuberculosis sensitive to isoniazid in combination with other anti-tuberculosis drugs; (2) prevention of tuberculosis; (3) according to the country
ST Tiansheng: 2024 Semi-Annual Report
